Texas Administrative Code
Title 22 - EXAMINING BOARDS
Part 9 - TEXAS MEDICAL BOARD
Chapter 170 - STANDARDS FOR USE OF INVESTIGATIONAL AGENTS
Subchapter B - INVESTIGATIONAL STEM CELL TREATMENTS FOR PATIENTS WITH CERTAIN SEVERE CHRONIC DISEASES OR TERMINAL ILLNESSES
Section 170.5 - General Standards for the Use of Investigational Stem Cell Treatments for Patients with Certain Severe Chronic Diseases or Terminal Illnesses

Universal Citation: 22 TX Admin Code § 170.5

Current through Reg. 50, No. 13; March 28, 2025

In accordance with Chapter 1003 of the Texas Health and Safety Code, physicians who administer or provide for the use of investigational stem cell treatments must:

(1) comply with all applicable state and federal laws and rules;

(2) be certified to administer stem cell in accordance with § 1003.055 of the Texas Health and Safety Code;

(3) ensure the patient is enrolled in a clinical trial investigating the use of adult stem cells in humans;

(4) maintain adequate medical records including documentation of the patient's qualifying severe chronic disease or terminal illness;

(5) obtain a signed written informed consent including the patient eligibility determination found in §1003.053(2)(a) of the Texas Health and Safety Code; and

(6) provide stem cells in a qualifying facility.

Disclaimer: These regulations may not be the most recent version. Texas may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.